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1 In rat pituitary tumour cells (GC cells), spontaneous oscillations of the intracellular
concentration of Ca2+ ([Ca2+]i) induce growth hormone (GH) secretion that is inhibited by
octreotide, a somatostatin (SRIF) agonist which binds to SRIF subtype (sst) receptor 2. The eects
of its functional activation on the control of [Ca2+]i were investigated using fluorimetric
measurements of [Ca2+]i.
2 SRIF decreases the basal [Ca2+]i and the [Ca
2+]i rise in response to forskolin (FSK) through the
inhibition of L-type voltage-dependent Ca2+ channels.
3 Pretreatment with octreotide or with L-Tyr8Cyanamid 154806, a sst2 receptor antagonist,
abolishes the SRIF-induced inhibition of [Ca2+]i. Octreotide is known to operate through agonist-
induced desensitization, while the antagonist operates through receptor blockade.
4 sst1 and sst2 receptor-immunoreactivities (-IRs) are localized to cell membranes. sst2, but not sst1
receptor-IR, internalizes after cell exposure to octreotide.
5 SRIF-induced inhibition of basal [Ca2+]i or FSK-induced Ca
2+ entry is blocked by pertussis
toxin (PTX).
6 FSK-induced cyclic AMP accumulation is only partially decreased by SRIF or octreotide, indicating
that sst2 receptors are coupled to intracellular pathways other than adenylyl cyclase (AC) inhibition.
7 In the presence of H-89, an inhibitor of cyclic AMP-dependent protein kinase (PKA), SRIF-
induced inhibition of basal [Ca2+]i is still present, although reduced in amplitude.
8 SRIF inhibits [Ca2+]i by activating sst2 receptors. Inhibition of AC activity is only partly
responsible for this eect, and other transduction pathways may be involved.
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Introduction
Modulation of the intracellular free Ca2+ concentration
([Ca2+]i) is critical for somatotroph function (Lussier et al.,
1991a; Cuttler et al., 1992). Indeed, the release of pituitary
growth hormone (GH) appears to be critically dependent on
changes in [Ca2+]i. In particular, in rat somatotrophs, growth
hormone-releasing hormone (GHRH) generates [Ca2+]i oscil-
lations that may periodically trigger GH release (Kwiecien et
al., 1997). Somatostatin (SRIF, somatotrophin release in-
hibitory factor) plays an important role in inhibiting rhythmic
[Ca2+]i transients (Kwiecien et al., 1997) either by directly
decreasing extracellular Ca2+ influx (Lussier et al., 1991c) or
by increasing K+ conductance, and thereby secondarily
decreasing Ca2+ influx (Lussier et al., 1991b). SRIF ability
to lower [Ca2+]i is responsible for its inhibitory action on GH
release (Lussier et al., 1991c).
The GC cell line is derived from a rat pituitary tumour
(subclone of the GH3 mammosomatotroph strain) and
represents a homogeneous in vitro model of tumour
somatotrophs (Mounier et al., 1995; Kwiecien et al., 1998).
In contrast to GH3 cells, GC cells release GH but not
prolactin. As normal somatotrophs, GC cells exibit rhythmic
[Ca2+]i oscillations resulting mainly from Ca
2+ entry through
L-type Ca2+ channels (Kwiecien et al., 1998). In contrast to
normal somatotrophs, however, [Ca2+]i transients do not
depend on GHRH, but they occur spontaneously. The
function of pacemaker activity in GC cells allows GH secretion
that is inhibited by the application of octreotide, a long-lasting
SRIF agonist (Mounier et al., 1995).
SRIF has been shown to play its multiple roles by
interacting with specific SRIF subtype (sst) receptors (see for
review Meyerhof, 1998). Five receptors have been identified to
date and designated sst1 through sst5 receptors, each
originating from a distinct gene (see for reference Hoyer et
al., 1995). Splice variants of the mouse sst2 receptor, sst2(a) and
sst2(b), have been cloned (Vanetti et al., 1992). These two
isoforms that originate from alternative splicing of the sst2
receptor mRNA dier in their coupling eciency to adenylyl
cyclase (AC) and in agonist-induced receptor desensitization
(Vanetti et al., 1993). In contrast, equivalent rat splice variants
display broadly similar pharmacological properties (Schindler
et al., 1998).
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